Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder.

Yang FQ, Huang JH, Liu M, Yang FP, Li W, Wang GC, Che JP, Zheng JH.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):340-7. eCollection 2014.

2.

Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.

Yan Y, Yang FQ, Zhang HM, Li J, Li W, Wang GC, Che JP, Zheng JH, Liu M.

Int J Clin Exp Pathol. 2014 Jun 15;7(7):4231-8. eCollection 2014.

3.

Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.

Liu JY, Li YH, Lin HX, Liao YJ, Mai SJ, Liu ZW, Zhang ZL, Jiang LJ, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D.

BMC Cancer. 2013 Jul 19;13:349. doi: 10.1186/1471-2407-13-349.

4.

Evaluation of Argonaute protein as a predictive marker for human clear cell renal cell carcinoma.

Li W, Liu M, Feng Y, Xu YF, Che JP, Wang GC, Zheng JH, Gao HJ.

Int J Clin Exp Pathol. 2013 May 15;6(6):1086-94. Print 2013.

5.

Protein phosphatase-2A is down-regulated in patients within clear cell renal cell carcinoma.

Li J, Sheng C, Li W, Zheng JH.

Int J Clin Exp Pathol. 2014 Feb 15;7(3):1147-53. eCollection 2014.

6.

Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.

Bi J, Chen X, Zhang Y, Li B, Sun J, Shen H, Kong C.

Urol Oncol. 2012 Sep;30(5):688-94. doi: 10.1016/j.urolonc.2010.08.001. Epub 2010 Oct 2.

PMID:
20888270
7.

The PIWI protein acts as a predictive marker for human gastric cancer.

Wang Y, Liu Y, Shen X, Zhang X, Chen X, Yang C, Gao H.

Int J Clin Exp Pathol. 2012;5(4):315-25. Epub 2012 Apr 19.

8.

Rsf-1/HBXAP overexpression is independent of gene amplification and is associated with poor outcome in patients with urinary bladder urothelial carcinoma.

Liang PI, Wu LC, Sheu JJ, Wu TF, Shen KH, Wang YH, Wu WR, Shiue YL, Huang HY, Hsu HP, Chen YH, Chen LT, Li CF, Liao AC.

J Clin Pathol. 2012 Sep;65(9):802-7. doi: 10.1136/jclinpath-2012-200897. Epub 2012 Jun 9.

PMID:
22685262
9.

PFKFB4 as a prognostic marker in non-muscle-invasive bladder cancer.

Yun SJ, Jo SW, Ha YS, Lee OJ, Kim WT, Kim YJ, Lee SC, Kim WJ.

Urol Oncol. 2012 Nov-Dec;30(6):893-9. doi: 10.1016/j.urolonc.2010.08.018. Epub 2011 Mar 10.

PMID:
21396842
10.

Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.

Otto W, Rubenwolf PC, Burger M, Fritsche HM, Rößler W, May M, Hartmann A, Hofstädter F, Wieland WF, Denzinger S.

BMC Cancer. 2012 Oct 8;12:459. doi: 10.1186/1471-2407-12-459.

11.

Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.

Kim JS, Chae Y, Ha YS, Kim IY, Byun SS, Yun SJ, Kim WJ.

Clin Genitourin Cancer. 2012 Jun;10(2):114-20. doi: 10.1016/j.clgc.2011.12.003. Epub 2012 Feb 28.

PMID:
22382007
12.

PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway.

Liu JY, Qian D, He LR, Li YH, Liao YJ, Mai SJ, Tian XP, Liu YH, Zhang JX, Kung HF, Zeng YX, Zhou FJ, Xie D.

Mol Cancer. 2013 Nov 23;12(1):148. doi: 10.1186/1476-4598-12-148.

13.

CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder.

Wang B, Wu S, Zeng H, Liu Z, Dong W, He W, Chen X, Dong X, Zheng L, Lin T, Huang J.

J Urol. 2015 Aug;194(2):556-62. doi: 10.1016/j.juro.2015.02.2941. Epub 2015 Mar 6.

PMID:
25752441
14.
15.

CIP2A is a predictor of survival and a novel therapeutic target in bladder urothelial cell carcinoma.

Xue Y, Wu G, Wang X, Zou X, Zhang G, Xiao R, Yuan Y, Long D, Yang J, Wu Y, Xu H, Liu F, Liu M.

Med Oncol. 2013 Mar;30(1):406. doi: 10.1007/s12032-012-0406-6. Epub 2012 Dec 30.

PMID:
23275123
16.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

17.

Osteopontin overexpression predicts poor prognosis of upper urinary tract urothelial carcinoma.

Ke HL, Chang LL, Yang SF, Lin HH, Li CC, Wu DC, Wu WJ.

Urol Oncol. 2011 Nov-Dec;29(6):703-9. doi: 10.1016/j.urolonc.2009.10.009. Epub 2009 Dec 21.

PMID:
20022267
18.

Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.

Ruan J, Wei B, Xu Z, Yang S, Zhou Y, Yu M, Liang J, Jin K, Huang X, Lu P, Cheng H.

Med Oncol. 2013 Mar;30(1):445. doi: 10.1007/s12032-012-0445-z. Epub 2013 Jan 10.

PMID:
23307254
19.

Prognostic significance of mucin expression in urothelial bladder cancer.

Stojnev S, Ristic-Petrovic A, Velickovic LJ, Krstic M, Bogdanovic D, Khanh do T, Ristic A, Conic I, Stefanovic V.

Int J Clin Exp Pathol. 2014 Jul 15;7(8):4945-58. eCollection 2014.

20.

Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer.

Boman K, Segersten U, Ahlgren G, Eberhard J, Uhlén M, Jirström K, Malmström PU.

BMC Urol. 2013 Apr 8;13:17. doi: 10.1186/1471-2490-13-17.

Supplemental Content

Support Center